Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||CHIR-124 + SN-38|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CHIR-124||CHIR124||CHK1 Inhibitor 17||CHIR-124 is a selective inhibitor of CHK1, which may enhance sensitivity of tumor cells to chemotherapeutic agents (PMID: 17255282, PMID: 22244109).|
|SN-38||SN 38|SN38||TOPO Inhibitor (Pan) 3||SN-38 is a metabolite of the topoisomerase inhibitor irinotecan, which causes cell cycle arrest and apoptotic induction, potentially leading to tumor growth inhibition (PMID: 21609311).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|TP53 inact mut||breast carcinoma||predicted - sensitive||CHIR-124 + SN-38||Preclinical - Cell culture||Actionable||In a preclinical study, SN-38 and CHIR-124 demonstrated synergy in a breast carcinoma cell line with defective TP53, resulting in increased cell cycle arrest and apoptosis in culture (PMID: 17255282).||17255282|
|TP53 loss||colon cancer||sensitive||CHIR-124 + SN-38||Preclinical - Cell culture||Actionable||In a preclinical study, a colon cancer cell line deficient in TP53 demonstrated increased sensitivity to sequential treatment with SN-38 and CHIR-124 compared to cells with wild-type TP53, resulting in increased apoptosis and micronucleation in culture (PMID: 17255282).||17255282|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|